Oral BPC-157 Capsules: What the Research Shows
Review published research on oral BPC-157 capsule administration. Animal study data on acid stability, bioavailability and gut protection.
BPC-157 is unique in peptide research. Nearly all bioactive peptides are vulnerable to being broken down by stomach acid. Most bioactive peptides need to undergo injections. BPC-157 doesn’t conform to this guideline. The peptide resists breakdown in stomach acid and remains stable at pH 1-2 for more than 24 hours. This fact has gotten confirmed in research. Given that BPC originates from human gastric juice, it was expected that it would have the property of acid resistance. However, just being stable does not mean that the peptide can get absorbed and act effectively.
Acid Stability - The Foundation of Oral BPC-157
Gastric acid sits at a pH between 1 and 2. Pepsin, the primary stomach protease, cleaves peptide bonds at that pH with high efficiency. Insulin, growth hormone, and most therapeutic peptides are degraded in this environment. BPC-157 is not. Sikiric et al., 2011 described BPC-157 as an "anti-ulcer peptidergic agent" that maintains its structure in gastric conditions for more than 24 hours. The peptide sequence GEPPPGKPADDAGLV contains 3 proline residues, which introduce rigid kinks in the backbone that may limit protease access. This is a measured physicochemical property, not a marketing claim.
Acid stability does not equate to absorption through the intestine. These are two separate biological events. A peptide can survive the stomach, reach the intestine, and still never permeate the epithelial surface. When assessing oral BPC-157, it is critical to distinguish between local gut activity and systemic absorption.
- Gastric acid stability
- >24 hours at pH 1-2 (Sikiric et al., 2011)
- Molecular weight
- 1,419.5 g/mol (15 amino acids)
- Oral bioavailability (rat)
- ~2-7% (Hsieh et al., 2022)
- Oral bioavailability (dog)
- ~3-5% (Hsieh et al., 2022)
- Human oral bioavailability
- No data exists
- Salt forms available
- Acetate salt, arginate salt (Na-BPC)
- FDA approval
- None for any route
Oral Administration in Published Animal Studies
Gastric Protection Models
The first study done on BPC-157 was on its effectiveness in the intestines. Sikiric et al., 1999 conducted studies in rats that had been given alcohol, NSAIDs, and subjected to stress. The results showed that oral administration of BPC-157 helped to diminish the damage in the stomach and preserve the mucosal vessels and the epithelium.
The concordance observed among the 3 injury types (chemical, pharmacological, psychological) builds reliability to the data. Indeed, BPC-157 did not simply have a role of blocking one of the pathways. It turned out that it played a role in the mucosal defense via various mechanisms like nitric oxide modulation and maintenance of blood vessels.
Colitis and Inflammatory Bowel Models
Researchers extended oral BPC-157 testing to lower GI models. TNBS-induced colitis (a chemical model that mimics features of Crohn's disease) and DSS-induced colitis (which produces features resembling ulcerative colitis) both responded to BPC-157 treatment. A 2012 study showed reduced colonic lesion scores and decreased inflammatory markers after BPC-157 administration. Both oral and systemic routes were effective, though the oral route delivered the peptide directly to the inflamed colon tissue.
Fistula Healing
A 2008 study tested oral and intraperitoneal BPC-157 in rats with colon-to-skin fistulas. Both routes achieved fistula closure. The oral route was slightly slower but reached the same endpoint. This study is significant because it demonstrated that oral and parenteral delivery could produce comparable outcomes for a gut-specific target. The mechanism involved modulation of the nitric oxide system.
| Study | Model | Species | Oral Dose Range | Key Finding |
|---|---|---|---|---|
| Sikiric et al., 1999 | Ethanol/NSAID gastric lesion | Rat | 10 ng/kg - 10 mcg/kg | Reduced gastric lesion area, preserved mucosa |
| Sikiric et al., 2011 | Review of gastric models | Rat (multiple studies) | Various | Confirmed acid stability, cytoprotective effects across models |
| Klicek et al., 2008 | Colon-to-skin fistula | Rat | 10 mcg/kg | Fistula closure via NO system modulation |
| Sikiric et al., 2012 | TNBS colitis | Rat | Oral and systemic | Reduced colonic lesion scores and inflammation |
Pharmacokinetics - What Gets Absorbed
BPC-157 plasma levels after oral administration were measured and observed in rats and dogs in an experiment by 2022 pharmacokinetic study. The findings showed that the medicine enters the bloodstream after its oral administration, but at levels much lower than those achieved by injection. The oral bioavailability was found to be about 2-7% for rats and 3-5% for dogs. The percentage of bioavailability when administered via intramuscular route was estimated to be in range of 14-19% in rats and 45-51% in dogs.
The results indicated that there were higher levels of bioavailability among dogs as compared to rats when either route of administration was taken into account. Since the gastrointestinal physiology of dogs provides a higher similarity to that of humans than that of rats, the results concerning dogs may be more indicative of absorption in humans. Nevertheless, this is pure speculation. No pharmacokinetic information on humans has ever been published for BPC-157 for any route of administration. Without such information, no proposed dosing protocol for the capsule has any scientific basis.
Arginate Salt and Formulation Differences
Two primary salt forms of BPC-157, namely acetate and arginate, are available in the market. The arginate salt form was used in many of the first Zagreb studies and may have varied solubility character than the acetate salt form more commonly sold by peptide retailers. A 2025 formulation review explained how the salt form may influence the dissolution speed, charge state, and interaction with gastro-intestinal fluid. Nonetheless, no studies directly comparing the bioavailability of acetate and arginate salt forms have been published.
Products in capsule forms are normally not clear about the type of salt they use. This has implications in transparency, as salt is part of the total weight of the material in capsules. For example, a capsule marked as “500 mcg BPC-157” using arginate salt will have different active peptide weight than a capsule which uses acetate salt. And if the label fails to mention the salt used, the customer cannot determine how much of the active peptide is present inside.
Capsule Formulations on the Market
Real Peptides sells BPC-157 capsules in a 100-count bottle at 500 mcg per capsule for $120. That provides 50 mg of total peptide content. PeptideGod does not sell BPC-157 in capsule form; their product is a lyophilized vial at $34.95. Capsule products from other vendors vary widely in stated dose, excipient list, and testing documentation.
If you are assessing any BPC-157 oral product, ask for a Certificate of Analysis with HPLC content testing for that specific batch. No less important are the following details: the specific form of the salt present in the product, the total peptide quantity in one capsule, and the list of excipients. With no data available for these parameters, there is no point in comparing the substance with any published studies on peptides.
What We Do Not Know
The gaps in oral BPC-157 knowledge are substantial. There is no human pharmacokinetic data. There is no controlled comparison between capsule and injectable forms in any species. There is no long-term oral safety study beyond the rodent data. There is no data on how excipients in commercial capsules affect peptide stability or release. There is no standardized manufacturing specification for oral BPC-157 products. Each of these unknowns matters. Together, they mean that anyone taking BPC-157 capsules is operating well outside the boundaries of published science.
FAQ - Oral BPC-157 Capsules
Does BPC-157 survive stomach acid?
Indeed. Laboratory assessments indicated that BPC-157 remained stable at a pH of 1-2 for a period greater than 24 hours (Sikiric et al., 2011). This characteristic makes it quite different from the majority of therapeutic peptides and is the reason why oral administration is deemed feasible.
Is there human bioavailability data for BPC-157 capsules?
No. The only oral bioavailability data comes from a 2022 study in rats and dogs. Human pharmacokinetics have not been measured for BPC-157 through any route.
What is the difference between acetate and arginate salt forms?
These are different counter-ions attached to the peptide. The arginate form (Na-BPC) was used in several original studies. The acetate form is common among commercial peptide suppliers. No published study directly compares their oral bioavailability or efficacy. See our dosage research page for more on reading capsule labels.
BPC-157 has not been authorized by the FDA for human consumption. Those planning to take BPC-157 orally are advised to seek the advice of a competent medical professional prior to use, especially if they are already taking prescription drugs or possess any significant health problems.
Compare the current picks
Prices, sizes and ratings side by side, updated when the merchant pages change.
See capsule picks